TR200103561T2 - Rodanin derivatives and their use in the prevention and imaging of amyloids - Google Patents

Rodanin derivatives and their use in the prevention and imaging of amyloids

Info

Publication number
TR200103561T2
TR200103561T2 TR2001/03561T TR200103561T TR200103561T2 TR 200103561 T2 TR200103561 T2 TR 200103561T2 TR 2001/03561 T TR2001/03561 T TR 2001/03561T TR 200103561 T TR200103561 T TR 200103561T TR 200103561 T2 TR200103561 T2 TR 200103561T2
Authority
TR
Turkey
Prior art keywords
imaging
rodanin
amyloids
prevention
derivatives
Prior art date
Application number
TR2001/03561T
Other languages
Turkish (tr)
Inventor
Elizabeth Augelli Szafran Corinne
Ann Glase Shelly
Stoeber Purchase Terri
Original Assignee
Warner Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Company filed Critical Warner Lambert Company
Publication of TR200103561T2 publication Critical patent/TR200103561T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Mevcut bulus Alzheimer hastaligini tedavi etmek için, bir formül (I) bilesiginin kullanildigi bir yöntem saglamaktadir. Bulus ayrica, amiloid proteinlerinin toplanmasini inhibe etmek için bir formül (I) bilesiginin kullanildigi bir yöntem ve amiloid birikintilerinin görüntülenmesi için sübstitüe edilm,is rodanin türevlerinin kullanildigi bir yöntem saglamaktadir.The present invention provides a method of using a compound of formula (I) to treat Alzheimer's disease. The invention also provides a method in which a compound of formula (I) is used to inhibit the aggregation of amyloid proteins and a substituted method for imaging amyloid deposits.

TR2001/03561T 1999-06-10 2000-05-31 Rodanin derivatives and their use in the prevention and imaging of amyloids TR200103561T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13854599P 1999-06-10 1999-06-10

Publications (1)

Publication Number Publication Date
TR200103561T2 true TR200103561T2 (en) 2002-04-22

Family

ID=22482518

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03561T TR200103561T2 (en) 1999-06-10 2000-05-31 Rodanin derivatives and their use in the prevention and imaging of amyloids

Country Status (8)

Country Link
EP (1) EP1192144A1 (en)
JP (1) JP2003502321A (en)
AU (1) AU5455400A (en)
BR (1) BR0011440A (en)
CA (1) CA2370316A1 (en)
MX (1) MXPA01009863A (en)
TR (1) TR200103561T2 (en)
WO (1) WO2000076988A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020394A1 (en) 2000-08-18 2002-06-21 Agouron Pharma PIRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
WO2003094916A1 (en) * 2002-05-10 2003-11-20 Qlt Inc. Methods of using thiazolidine derivatives to treat cancer or inflammation
CA2486138A1 (en) * 2002-05-17 2003-11-27 Qlt Inc. Methods of using thiazolidinedithione derivatives
EP1569653A1 (en) 2002-12-06 2005-09-07 Warner-Lambert Company LLC Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
JP2006526017A (en) * 2003-05-14 2006-11-16 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
WO2005007123A2 (en) * 2003-07-18 2005-01-27 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US20100204230A1 (en) 2007-02-12 2010-08-12 Peter Blurton Piperazine derivatives for treatment of ad and related conditions
JP2012500222A (en) * 2008-08-15 2012-01-05 バーンハム インスティテュート フォー メディカル リサーチ Compositions and methods for the design and development of metalloenzyme inhibitors
EP2399612B1 (en) * 2009-12-25 2018-02-21 Canon Kabushiki Kaisha Composition for labeling tissues of central nervous system, method for labeling tissues of central nervous system, and screening method using the composition for labeling tissues of central nervous system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D

Also Published As

Publication number Publication date
WO2000076988A1 (en) 2000-12-21
JP2003502321A (en) 2003-01-21
CA2370316A1 (en) 2000-12-21
EP1192144A1 (en) 2002-04-03
AU5455400A (en) 2001-01-02
MXPA01009863A (en) 2002-05-06
BR0011440A (en) 2002-03-19

Similar Documents

Publication Publication Date Title
EA200201247A1 (en) CONNECTIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DE60126980D1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES
ATE314343T1 (en) COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
EA200000723A1 (en) DERIVATIVES 2- (PURIN-9-IL) -TETRAHYDROFURAN-3,4-DIOLA
EA199900778A1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE TO INHIBIT β-AMYLOID PEPTIDE
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
EA200401114A2 (en) SUBSTITUTED HYDROXYETHYLAMINES
EA200400162A1 (en) N- (3-AMINO-2-HYDROXYPROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
BR0308243A (en) Compound, pharmaceutical formulation, and, methods of treating diabetes, alzheimer's disease, and inhibiting gsk-3 in a mammal
ATE185797T1 (en) STILBEN DERIVATIVES USABLE AS CYCLOOXYGENASE-2 INHIBITORS
ES2188584T3 (en) AMINA HETEROCICLICAL DERIVATIVES.
ATE147981T1 (en) ADMINISTRATION OF LAMOTRIGINE FOR THE TREATMENT OF NEURO-AIDS
BR0212787A (en) Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition
BG106293A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
DE60115466D1 (en) ACTIVE PROCESSORS OF IMIDAZOPYRIDINE DERIVATIVES
TR200103561T2 (en) Rodanin derivatives and their use in the prevention and imaging of amyloids
EA200300392A1 (en) Derivatives of piperazine with a bridge connection
DK1553985T3 (en) Biphenyls as imaging agents in Alzheimer's disease
TR200103562T2 (en) Rhodanine derivatives for use in the method of preventing amyloid protein aggregation and imaging amyloid deposits
PT986393E (en) USING A NITROXIDE OR ITS PRO-PHARMACY IN THE CANCER'S PROFILACTIC AND THERAPEUTIC TREATMENT
ATE425756T1 (en) USE OF CARBAMAZEPINE DERIVATIVES TO TREAT AGITATIO IN DEMENTIA PATIENTS
DE69710574D1 (en) DICLOFENAC / GAMMA-CYCLODEXTRIN KLATHRAT COMPONENT